Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AtriCure (ATRC) Short-term Investments (2016 - 2024)

Historic Short-term Investments for AtriCure (ATRC) over the last 16 years, with Q2 2024 value amounting to $8.0 million.

  • AtriCure's Short-term Investments fell 8664.38% to $8.0 million in Q2 2024 from the same period last year, while for Jun 2024 it was $8.0 million, marking a year-over-year decrease of 8664.38%. This contributed to the annual value of $53.0 million for FY2023, which is 1593.14% down from last year.
  • Latest data reveals that AtriCure reported Short-term Investments of $8.0 million as of Q2 2024, which was down 8664.38% from $41.0 million recorded in Q1 2024.
  • In the past 5 years, AtriCure's Short-term Investments registered a high of $202.3 million during Q4 2020, and its lowest value of $8.0 million during Q2 2024.
  • For the 5-year period, AtriCure's Short-term Investments averaged around $85.5 million, with its median value being $68.9 million (2022).
  • As far as peak fluctuations go, AtriCure's Short-term Investments skyrocketed by 32891.08% in 2020, and later tumbled by 8664.38% in 2024.
  • AtriCure's Short-term Investments (Quarter) stood at $202.3 million in 2020, then crashed by 62.71% to $75.4 million in 2021, then fell by 16.47% to $63.0 million in 2022, then dropped by 15.93% to $53.0 million in 2023, then plummeted by 84.93% to $8.0 million in 2024.
  • Its Short-term Investments stands at $8.0 million for Q2 2024, versus $41.0 million for Q1 2024 and $53.0 million for Q4 2023.